ArticleHaematologica2025
Clinical characteristics and therapeutic determinants of
Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical characteristics and prognosis of therapy-related acute myeloid leukemia patients with RUNX1::RUNX1T1.BMC cancer · 2026Article
- Article
- Nomogram-based prediction models for clinical outcomes in pediatricFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Core binding factor acute myeloid leukemia (CBF-AML) includes RUNX1::RUNX1T1 and CBFB::MYH11 AML. To investigate whether they should be regarded as distinct entities and treated separately, we retrospectively analyzed 536 patients with CBFAML aged 60 years or younger. For CBFB::MYH11 AML, no outcome differences were observed between standard-dose (SD) and intermediate-dose (ID) cytarabine induction, with 5-year overall survival (OS) and relapse-free survival (RFS) at 86.4% versus 85.3% (P=0.99) and 74.1% versus 68.4% (P=0.93), respectively. However, ID induction improved the outcomes of RUNX- 1::RUNX1T1 AML, with 5-year OS and RFS rates of 77.7% versus 60.3% (P<0.001) and 71.4% versus 54.1% (P<0.001), respectively. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) improved CBFB::MYH11 patients' RFS but not OS for both the entire CBFB::MYH11 cohort and patients with a measurable residual disease (MRD) <3-log reduction after two courses of chemotherapy. Allo-HSCT improved survival of RUNX1::RUNX1T1 patients with MRD <3-log reduction when receiving SD induction, with 5-year OS and RFS rates for transplantation versus non-transplantation of 71.9% versus 43.6% (P=0.023) and 72.9 % versus 35.0% (P=0.001), while conferring no additional benefits for those with ID regimen, with a 5-year OS and RFS of 35.6% versus 71.2% (P=0.73) and 37.4% versus 60.7% (P=0.71), respectively. Overall, our study suggests that RUNX1::RUNX1T1 and CBFB::MYH11 AML are different entities and should be treated with distinct strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.